【纪实】凯莱英化学大分子基地顺利通过美国FDA批准前检查

同花顺
Sep 21

凯莱英(HK6821)化学大分子基地生产的某原料药(884143)项目,于2026年6月底至7月初完成了美国食品药品监督管理局(FDA)的批准前检查(PAI),并于8月底收到FDA签发的工厂检查报告(EIR),标志着公司合规能力再次获得美国药监体系权威认可。此次FDA PAI检查,是公司化学大分子基地首次接受FDA检查,标志着已具备采用成熟、合规的先进工艺开展规模化生产与常态化运营的能力,能够对标...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10